Last reviewed · How we verify
NCT06186375
Performance of PEAR 2.0 Software in Prescribing Biotherapy in Patients With Rheumatoid Arthritis
trial testing Patients with planned biotherapy in Polyarthritis; Rheumatoid in 239 participants. Participants enrolled and being followed up; not accepting new ones.
30 November 2025
Quick facts
| Lead sponsor | CEN Biotech |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 239 |
| Start date | 5 May 2023 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 March 2026 |
| Sites | 4 locations across France |
Drugs / interventions tested
- Patients with planned biotherapy
Conditions studied
- Polyarthritis; Rheumatoid — all drugs for Polyarthritis; Rheumatoid →
Sponsor
CEN Biotech — full company profile →
Who can join
18 and older, any sex, with Polyarthritis; Rheumatoid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The management of rheumatoid arthritis is based on the prescription of disease-modifying anti-rheumatic drugs (DMARDs) to induce clinical and biological remission. If the first line of treatment (methotrexate) fails, a biotherapy may be prescribed. In daily practice, the initiation of a targeted therapy must therefore be based on the prescriber's expertise or qualification in terms of his or her level of experience in the diagnosis and management of chronic inflammatory rheumatic diseases such as rheumatoid arthritis. As the therapeutic arsenal has expanded, so has the question of choosing the right treatment for the right patient at the right time. At present, in daily practice, there is no tool to help clinicians predict treatment efficacy. The choice of biotherapy based on efficacy carries relatively little weight, firstly because this choice is made in relation to other biotherapies, and secondly because there are no superiority studies that have actually demonstrated greater efficacy in favor of one of the targeted therapies. In the age of Big Data, artificial intelligence can be used to develop algorithms for predicting treatment response. mYXpression has developed medical decision support software based on the integration of transcriptomic markers to assess the probability of response and/or non-response to biotherapies for each patient. The algorithm's performance was theoretically tested by retrospectively collecting transcriptomic data and clinical responses to 6 biotherapies from 992 patients included in 17 clinical trials or cohorts. The aim of this observational study is to demonstrate the value of PEAR 2.0 medical decision support software in the management of rheumatoid arthritis patients who are candidates for biotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06186375
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other CEN Biotech trials
Trials by the same sponsor.
- NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
- NCT07295678 — URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis · NA · not yet recruiting
- NCT06617975 — Knee Osteoarthritis and Spa Therapy · NA · recruiting
- NCT06278324 — Effectiveness of a Nasal Spray on Viral Respiratory Infections · NA · completed
- NCT06054737 — Chronic Venous Insufficiency and Balneotherapy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06186375 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CEN Biotech
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06186375.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing